Analysts at Leerink Swann began coverage on shares of Bioverativ Inc (OTC:BIVV) in a research report issued on Wednesday. The brokerage set an “outperform” rating and a $56.00 price target on the stock.

A number of other equities research analysts have also weighed in on BIVV. Gabelli initiated coverage on shares of Bioverativ in a research note on Thursday, February 2nd. They set a “buy” rating and a $58.00 target price for the company. Morgan Stanley initiated coverage on shares of Bioverativ in a research note on Thursday, February 2nd. They set an “underweight” rating and a $41.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Bioverativ in a research note on Friday, February 3rd. They set a “buy” rating and a $54.00 target price for the company. Piper Jaffray Companies initiated coverage on shares of Bioverativ in a research note on Monday, February 6th. They set a “neutral” rating for the company. Finally, Raymond James Financial, Inc. initiated coverage on shares of Bioverativ in a research note on Tuesday, February 7th. They set a “strong-buy” rating and a $59.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $53.60.

Analyst Recommendations for Bioverativ (OTC:BIVV)

Shares of Bioverativ (OTC:BIVV) opened at 44.10 on Wednesday. Bioverativ has a 52 week low of $41.88 and a 52 week high of $46.40. The firm’s 50-day moving average price is $43.86 and its 200 day moving average price is $43.86.

This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The correct version of this article can be read at http://www.watchlistnews.com/leerink-swann-initiates-coverage-on-bioverativ-inc-bivv/1121512.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.